Dr. Lee Richstone

Dr. Simon J Hall MD is a board certified urologist with Fellowship training in Urologic Oncology. His clinical interests include the diagnosis and treatment of Prostate, Bladder and Kidney cancers. He is especially interested in Active Surveillance of men with prostate cancer and men and women with incidentally found small renal masses and the creation of continent urinary reconstructions for patients who need to undergo cystectomy for Bladder cancer. Furthermore, Dr. Hall has a keen interest in treating patients with recurrent prostate cancer following definitive therapy. He believes that objective & balanced communication with the patient and family is the key to decision making and individualized care. Over the years Dr. Hall has been named as Best Doctor, both nationally and regionally, by organizations such as Castle Connolly, SuperDoctors and New York Magazine. Dr. Hall s research has focused of new therapies for prostate and bladder cancer; he has participated in numerous clinical trials, some of which generated data resulting in FDA approval of Sipleucel-T (Provenge) and enzulutamide (Xtandi). He oversees a laboratory investigating novel approaches to negating the Androgen Receptor, an important key driver of castration resistant prostate cancer. Decision making and improved methods of clinical care for patients with bladder and prostate cancer are important aspects of his research interests in collaboration with Dr. Michael Diefenbach, a behavioral scientist in the Departments of Urology & Medicine at NS-LIJ. He has authored or co-authored nearly 70 peer reviewed articles in Journals such as Journal of Urology, Urology, British Journal of Urology, Clinical Cancer Research and Science. Dr. Hall received his MD from the College of Physicians & Surgeons of Columbia University. He then completed two years of Surgery training at the Mount Sinai Medical Center followed by a four year residency in Urology at Boston University School of Medicine. This was followed by a 2 year fellowship in Urologic Oncology in the Scott Department of Urology at Baylor College of Medicine. Prior to joining the Smith Institute for Urology, he served on the faculty of Icahn School of Medicine at Mount Sinai for 18 years, holding various positions including Kyung Hyun Kim MD Chair of Urology and the Director of the Deane Prostate Health & Research Center. Dr. Hall is rated as a Distinguished provider by MediFind in the treatment of Hydronephrosis. His top areas of expertise are Muscle Invasive Bladder Cancer, Prostate Cancer, Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery.

Daniel Sagalovich is an Oncologist and an Urologist in Staten Island, New York. Dr. Sagalovich is rated as an Advanced provider by MediFind in the treatment of Hydronephrosis. His top areas of expertise are Renal Cell Carcinoma (RCC), Obstructive Uropathy, Ureterocele, Nephrectomy, and Ureteroscopy.

Louis Kavoussi, MD, MBA, Director of teleintervention at Northwell. He is a world-renowned urologic surgeon who brings more than 30 years of specialized expertise in minimally invasive urological surgery. His area of focus includes treating a wide range of urologic diseases, including kidney obstructions, renal stones and urologic cancer. At the forefront of innovation, Dr. Kavoussi pioneered several new surgical techniques, including the first minimally invasive approaches to kidney surgery for kidney cancer and kidney donation. He was also part of the team that performed the first laparoscopic prostate removal for cancer. In 1999, Dr. Kavoussi received a Smithsonian Computerworld Permanent Collection award for his work in developing telerounding, the starting point of telehealth medicine-to facilitate physician communication with hospitalized patients. Before joining Northwell in 2005 as chair of urology, Dr. Kavoussi completed his medical degree at the State University of New York at Buffalo. He obtained his urologic training at Washington University of St. Louis and, directly following residency, was named chief of urology at the Jewish Hospital of St. Louis. In 1991, he was appointed assistant professor at Harvard School of Medicine and director of endourology at the Brigham and Women's Hospital. In 1993, he joined the faculty of Johns Hopkins University School of Medicine, where he was vice chairman of urology and named a Patrick C. Walsh Distinguished Professor. Dr. Kavoussi values a team approach to care, and often collaborates with other specialists to create personalized and comprehensive treatment plans. His patients appreciate his easygoing personality and thoughtfulness. As the Waldbaum-Gardner Distinguished Professor of Urology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Dr. Kavoussi is passionate about training the next generation of surgeons. He has presented his work and given live surgical demonstrations at conferences around the world and has more than 500 academic publications. Dr. Kavoussi is rated as an Elite provider by MediFind in the treatment of Hydronephrosis. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Nephrectomy, and Reconstructive Urology Surgery.